Health Care • Medical/Dental Instruments
$291.86 ▼ -19.89
(-6.38%)
MKT CAP: $111.95B • VOL: 6.44M
52W L $267 52W H $389
SYK // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $25.12B | $22.59B | $20.50B |
| YoY Revenue Growth % | +11.2% | +10.2% | — |
| Gross Profit | $16.07B | $14.44B | — |
| Gross Margin % | 64.0% | 63.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $4.89B | $3.69B | $3.89B |
| Operating Margin % | 19.5% | 16.3% | 19.0% |
| Net Income (GAAP) | $3.25B | $2.99B | $3.17B |
| EBITDA (Normalized) | $5.50B | $4.29B | $4.63B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $5.04B | $4.24B | $3.71B |
| Capital Expenditures (CapEx) | $761.0M | $755.0M | $922.4M |
| Free Cash Flow (FCF) | $4.28B | $3.49B | $2.79B |
| FCF Margin % | 17.1% | 15.4% | 13.6% |
| Return on Invested Capital (ROIC %) | 11.6% | 10.0% | 7.7% |
| Cash & Short-Term Equivalents | $4.01B | $3.65B | — |
| Total Debt (Short + Long Term) | $14.86B | $12.19B | $15.39B |
| Total Stockholders' Equity | $22.42B | $20.63B | $31.57B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SYK.